NCIt definition : A human monoclonal antibody directed against the immunosuppressive ligand programmed
cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration,
socazolimab specifically targets and binds to PD-L1, blocking its binding to and activation
of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279).
This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the
cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing
tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding
to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1,
a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed
on activated T-cells, is a negative regulator of the immune system that limits the
expansion and survival of CD8-positive T-cells.;
UNII : 82P4S8Q3FB;
CAS number : 2305043-30-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2305043-30-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : STI A1014; STI-A1014; ZKAB-001; ZKAB 001;
Semantic type(s)